Article summary
FDA Floats Ibogaine Trial Design, Asks Field for Input On Monday, the day FDA’s Considerations for Potential Future Therapeutic Use of Psychedelic Drugs public comment period closed, the agency issued a request for information (RFI) related to clinical studies of ibogaine. In the notice, FDA outlines a potential early-stage ibogaine clinical trial design, which it […]
Continue to the original publication for the complete article.